Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

Sponsor
Sun Yat-sen University
Study ID
NCT04586088
Phase
PHASE2
Status
Unknown

Conditions

  • Chemotherapy Effect
  • Immunotherapy
  • Metastatic Nasopharyngeal Carcinoma
  • Molecular Targeted Therapy
  • Nasopharyngeal Carcinoma
  • Recurrent Nasopharyngeal Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib plus Camrelizumab — DRUG
    Subjects receive Apatinib, 250mg, QD and Camrelizumab, 200mg, D1, Q3W. Treatment was continued until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or investigator decision.

Study Details

This is a prospective phase II clinical trial to evaluate the efficacy and safety of apatinib and camrelizumab in recurrent or metastatic nasopharyngeal carcinoma who failed at least the first-line treatment.

Key Dates

Start date
May 5, 2020
Status verified
May 2023
Primary completion
Jun 2, 2022
Completion
Sep 5, 2023

Study Design

Enrollment
58 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib plus Camrelizumab arm
    Subjects receive apatinib plus camrelizumab

Primary Outcome Measure

Objective response rate [ Time Frame: 1 year ]

Related Studies